BIO-TECHNE Corp Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
BIO-TECHNE Corp (TECH) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $35.24 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-08-23.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2023-08-23
- BIO-TECHNE Corp proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-06-30 was $6.08M.
- BIO-TECHNE Corp proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-03-31 was $2.65M, a 80.51% decline year-over-year.
- BIO-TECHNE Corp proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-12-31 was $12.00M.
- BIO-TECHNE Corp proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-09-30 was $14.51M, a 16.54% increase year-over-year.
- BIO-TECHNE Corp proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $35.24M, a 35.24% increase from fiscal 2022.
- BIO-TECHNE Corp proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $26.05M, a 60.75% decline from fiscal 2021.
- BIO-TECHNE Corp proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $66.38M, a 54.88% decline from fiscal 2020.
- BIO-TECHNE Corp proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2020 was $147.12M, a 581.77% increase from fiscal 2019.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|
| 2023-06-30 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $8.73M derived: sum of 2 quarters · filed 2023-08-23 | $20.73M derived: sum of 3 quarters · filed 2023-08-23 | $35.24M 10-K · filed 2023-08-23 | |
| 2023-03-31 | $2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-08 | $14.65M derived: sum of 2 quarters · filed 2023-05-08 | $29.16M 10-Q · filed 2023-05-08 | $29.16M derived: sum of 4 quarters · filed 2023-08-23 | |
| 2022-12-31 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-07 | $26.51M 10-Q · filed 2023-02-07 | $26.51M derived: sum of 3 quarters · filed 2023-08-23 | $40.11M derived: sum of 4 quarters · filed 2023-08-23 | |
| 2022-09-30 | $14.51M 10-Q · filed 2022-11-07 | $14.51M derived: sum of 2 quarters · filed 2023-08-23 | $28.11M derived: sum of 3 quarters · filed 2023-08-23 | $28.11M derived: sum of 4 quarters · filed 2023-08-23 | |
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $13.61M derived: sum of 2 quarters · filed 2023-08-23 | $13.61M derived: sum of 3 quarters · filed 2023-08-23 | $26.05M 10-K · filed 2023-08-23 | |
| 2022-03-31 | $13.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-08 | $13.61M derived: sum of 2 quarters · filed 2023-05-08 | $26.05M 10-Q · filed 2023-05-08 | $26.05M derived: sum of 4 quarters · filed 2023-08-23 | |
| 2021-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-07 | $12.45M 10-Q · filed 2023-02-07 | $12.45M derived: sum of 3 quarters · filed 2023-08-23 | $35.68M derived: sum of 4 quarters · filed 2023-08-23 | |
| 2021-09-30 | $12.45M 10-Q · filed 2022-11-07 | $12.45M derived: sum of 2 quarters · filed 2023-08-23 | $35.68M derived: sum of 3 quarters · filed 2023-08-23 | $49.79M derived: sum of 4 quarters · filed 2023-08-23 | |
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $23.23M derived: sum of 2 quarters · filed 2023-08-23 | $37.34M derived: sum of 3 quarters · filed 2023-08-23 | $66.38M 10-K · filed 2023-08-23 | |
| 2021-03-31 | $23.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-09 | $37.34M derived: sum of 2 quarters · filed 2022-05-09 | $66.38M 10-Q · filed 2022-05-09 | $90.83M derived: sum of 4 quarters · filed 2022-08-24 | |
| 2020-12-31 | $14.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-07 | $43.15M 10-Q · filed 2022-02-07 | $67.60M derived: sum of 3 quarters · filed 2022-08-24 | $121.87M derived: sum of 4 quarters · filed 2022-08-24 | |
| 2020-09-30 | $29.04M 10-Q · filed 2021-11-08 | $29.04M 10-Q · filed 2020-11-09 | $107.76M derived: sum of 3 quarters · filed 2022-08-24 | $164.85M derived: sum of 4 quarters · filed 2022-08-24 | |
| 2020-06-30 | $24.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-24 | $78.72M derived: sum of 2 quarters · filed 2022-08-24 | $135.81M derived: sum of 3 quarters · filed 2022-08-24 | $147.12M 10-K · filed 2022-08-24 | |
| 2020-03-31 | $54.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-07 | $111.36M derived: sum of 2 quarters · filed 2021-05-07 | $122.67M 10-Q · filed 2021-05-07 | $127.03M derived: sum of 4 quarters · filed 2021-08-25 | |
| 2019-12-31 | $57.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-08 | $68.40M 10-Q · filed 2021-02-08 | $72.76M derived: sum of 3 quarters · filed 2021-08-25 | $84.64M derived: sum of 4 quarters · filed 2021-08-25 | |
| 2019-09-30 | $11.31M 10-Q · filed 2019-11-06 | $11.31M 10-Q · filed 2020-11-09 | $27.56M derived: sum of 3 quarters · filed 2021-08-25 | $32.89M derived: sum of 4 quarters · filed 2021-08-25 | |
| 2019-06-30 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-25 | $16.25M derived: sum of 2 quarters · filed 2021-08-25 | $21.58M derived: sum of 3 quarters · filed 2021-08-25 | $21.58M 10-K · filed 2021-08-25 | |
| 2019-03-31 | $11.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-11 | $17.21M derived: sum of 2 quarters · filed 2020-05-11 | $17.21M 10-Q · filed 2020-05-11 | $47.04M derived: sum of 4 quarters · filed 2020-08-26 | |
| 2018-12-31 | $5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-06 | $5.33M 10-Q · filed 2020-02-06 | $35.16M derived: sum of 3 quarters · filed 2020-08-26 | $35.16M derived: sum of 4 quarters · filed 2020-08-26 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-06 | $29.83M derived: sum of 2 quarters · filed 2020-08-26 | $29.83M derived: sum of 3 quarters · filed 2020-08-26 | $32.89M derived: sum of 4 quarters · filed 2020-08-26 | |
| 2018-06-30 | $29.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-26 | $29.83M derived: sum of 2 quarters · filed 2020-08-26 | $32.89M derived: sum of 3 quarters · filed 2020-08-26 | $36.39M 10-K · filed 2020-08-26 | |
| 2018-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-07 | $3.06M derived: sum of 2 quarters · filed 2019-05-07 | $6.56M 10-Q · filed 2019-05-07 | $9.02M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2017-12-31 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-07 | $6.56M 10-Q · filed 2019-02-07 | $9.02M derived: sum of 3 quarters · filed 2019-11-06 | $11.05M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2017-09-30 | $3.50M 10-Q · filed 2018-11-07 | $5.96M derived: sum of 2 quarters · filed 2019-11-06 | $3.50M 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | $2.46M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-11-06 | $4.49M derived: sum of 2 quarters · filed 2019-11-06 | $6.08M 10-K/A · filed 2019-11-06 | ||
| 2017-03-31 | $2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $3.62M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $1.59M 10-Q · filed 2018-02-08 | ||||
| 2016-06-30 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-27 | -$3.15M derived: sum of 2 quarters · filed 2018-08-27 | -$3.15M derived: sum of 3 quarters · filed 2018-08-27 | $776.00K 10-K · filed 2018-08-27 | |
| 2016-03-31 | -$3.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | -$3.15M derived: sum of 2 quarters · filed 2017-05-10 | $780.00K 10-Q · filed 2017-05-10 | $2.25M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $3.93M 10-Q · filed 2017-02-09 | $5.40M derived: sum of 3 quarters · filed 2017-09-07 | $7.52M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-09-30 | $3.93M 10-Q · filed 2016-11-09 | $5.40M derived: sum of 2 quarters · filed 2017-09-07 | $7.52M derived: sum of 3 quarters · filed 2017-09-07 | $7.52M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-06-30 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $3.59M derived: sum of 2 quarters · filed 2017-09-07 | $3.59M derived: sum of 3 quarters · filed 2017-09-07 | $13.47M 10-K · filed 2017-09-07 | |
| 2015-03-31 | $2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10 | $2.12M derived: sum of 2 quarters · filed 2016-05-10 | $12.00M 10-Q · filed 2016-05-10 | $254.65M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | $9.88M 10-Q · filed 2016-02-09 | $252.54M derived: sum of 3 quarters · filed 2016-08-29 | $265.10M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-09-30 | $9.88M 10-Q · filed 2015-11-09 | $252.54M derived: sum of 2 quarters · filed 2016-08-29 | $265.10M derived: sum of 3 quarters · filed 2016-08-29 | $283.20M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-06-30 | $242.66M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29 | $255.22M derived: sum of 2 quarters · filed 2016-08-29 | $273.32M derived: sum of 3 quarters · filed 2016-08-29 | $289.41M 10-K · filed 2016-08-29 | $59.44M 10-K · filed 2014-08-29 |
| 2014-03-31 | $12.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | $30.66M derived: sum of 2 quarters · filed 2015-05-11 | $46.75M 10-Q · filed 2015-05-11 | $96.38M derived: sum of 4 quarters · filed 2015-08-31 | |
| 2013-12-31 | $18.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09 | $34.19M 10-Q · filed 2015-02-09 | $83.82M derived: sum of 3 quarters · filed 2015-08-31 | $115.48M derived: sum of 4 quarters · filed 2015-08-31 | |
| 2013-09-30 | $16.09M 10-Q · filed 2014-11-10 | $65.71M derived: sum of 2 quarters · filed 2015-08-31 | $97.38M derived: sum of 3 quarters · filed 2015-08-31 | $108.10M derived: sum of 4 quarters · filed 2015-08-31 | |
| 2013-06-30 | $49.62M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $81.29M derived: sum of 2 quarters · filed 2015-08-31 | $92.01M derived: sum of 3 quarters · filed 2015-08-31 | $103.61M 10-K · filed 2015-08-31 | $62.10M 10-K · filed 2013-08-29 |
| 2013-03-31 | $31.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-12 | $42.39M derived: sum of 2 quarters · filed 2014-05-12 | $53.99M 10-Q · filed 2014-05-12 | $65.15M derived: sum of 4 quarters · filed 2014-08-29 | |
| 2012-12-31 | $10.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-04 | $22.32M 10-Q · filed 2014-02-04 | $33.48M derived: sum of 3 quarters · filed 2014-08-29 | $52.82M derived: sum of 4 quarters · filed 2014-08-29 | |
| 2012-09-30 | $11.60M 10-Q · filed 2013-11-12 | $22.76M derived: sum of 2 quarters · filed 2014-08-29 | $42.10M derived: sum of 3 quarters · filed 2014-08-29 | $54.27M derived: sum of 4 quarters · filed 2014-08-29 | |
| 2012-06-30 | $11.16M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $30.50M derived: sum of 2 quarters · filed 2014-08-29 | $42.67M derived: sum of 3 quarters · filed 2014-08-29 | $67.44M 10-K · filed 2014-08-29 | |
| 2012-03-31 | $19.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-10 | $31.51M derived: sum of 2 quarters · filed 2013-05-10 | $56.27M 10-Q · filed 2013-05-10 | $63.93M derived: sum of 4 quarters · filed 2013-08-29 | |
| 2011-12-31 | $12.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-11 | $36.94M 10-Q · filed 2013-02-11 | $44.59M derived: sum of 3 quarters · filed 2013-08-29 | $52.00M derived: sum of 4 quarters · filed 2013-08-29 | |
| 2011-09-30 | $24.76M 10-Q · filed 2012-11-09 | $32.42M derived: sum of 2 quarters · filed 2013-08-29 | $39.83M derived: sum of 3 quarters · filed 2013-08-29 | $41.96M derived: sum of 4 quarters · filed 2013-08-29 | |
| 2011-06-30 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-29 | $15.07M derived: sum of 2 quarters · filed 2013-08-29 | $17.19M derived: sum of 3 quarters · filed 2013-08-29 | $39.50M 10-K · filed 2013-08-29 | |
| 2011-03-31 | $7.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-10 | $9.54M derived: sum of 2 quarters · filed 2012-05-10 | $31.85M 10-Q · filed 2012-05-10 | $44.98M derived: sum of 4 quarters · filed 2012-08-29 | |
| 2010-12-31 | $2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-07 | $24.43M 10-Q · filed 2012-02-07 | $37.56M derived: sum of 3 quarters · filed 2012-08-29 | $51.58M derived: sum of 4 quarters · filed 2012-08-29 | |
| 2010-09-30 | $22.31M 10-Q · filed 2011-11-09 | $35.44M derived: sum of 2 quarters · filed 2012-08-29 | $49.46M derived: sum of 3 quarters · filed 2012-08-29 | $56.64M derived: sum of 4 quarters · filed 2012-08-29 | |
| 2010-06-30 | $13.13M derived: 10-K 12 month − 10-Q 9 month · filed 2012-08-29 | $27.15M derived: sum of 2 quarters · filed 2012-08-29 | $34.33M derived: sum of 3 quarters · filed 2012-08-29 | $39.55M 10-K · filed 2012-08-29 | |
| 2010-03-31 | $14.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-05-10 | $21.20M derived: sum of 2 quarters · filed 2011-05-10 | $26.43M 10-Q · filed 2011-05-10 | ||
| 2009-12-31 | $7.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-02-09 | $12.40M 10-Q · filed 2011-02-09 | |||
| 2009-09-30 | $5.22M 10-Q · filed 2010-11-09 | ||||
| 2009-06-30 | $34.31M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |